Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom completed enrollment in its Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA for eosinophilic esophagitis (EoE), dosing 95 patients across 41 U.S. sites ahead of schedule. This trial is the first large, placebo-controlled study of an acid suppression treatment in EoE, a condition with few approved therapies where PPIs are commonly used off-label.
Key figures
- Drug Name
- VOQUEZNA (vonoprazan)
- Phase Of Trial
- Phase 2
- Site count
- 41
- Patient count
- 95
- Topline results timing
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.